Targeting ubiquitin in cancers - PubMed (original) (raw)
Review
. 2006 Dec;42(18):3095-102.
doi: 10.1016/j.ejca.2006.05.041. Epub 2006 Nov 2.
Affiliations
- PMID: 17084074
- DOI: 10.1016/j.ejca.2006.05.041
Review
Targeting ubiquitin in cancers
Ivan Dikic et al. Eur J Cancer. 2006 Dec.
Abstract
Ubiquitin (Ub) is a small protein modifier involved in cellular functions such as cell cycle, apoptosis, cell signalling, endocytosis, transcription and DNA repair. Ubiquitin operates as a reversible and highly versatile regulatory signal, which may be read and interpreted by an expanding number of Ub-binding domains (UBD). There is accumulating evidence that mutations or altered expression of ubiquitylating or de-ubiquitylating enzymes as well as of Ub-binding proteins affect crucial mediators of such functions and are found in several malignancies. Here we discuss how oncogenic alterations in the Ub system can be targeted by anti-cancer therapies.
Similar articles
- Proteasome inhibitors in pediatric cancer treatment.
Bachmann AS. Bachmann AS. Hawaii Med J. 2008 Sep;67(9):247-9. Hawaii Med J. 2008. PMID: 18853901 - The role of the ubiquitin/proteasome system in cellular responses to radiation.
McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. McBride WH, et al. Oncogene. 2003 Sep 1;22(37):5755-73. doi: 10.1038/sj.onc.1206676. Oncogene. 2003. PMID: 12947384 Review. - NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Cusack JC Jr, Liu R, Xia L, Chao TH, Pien C, Niu W, Palombella VJ, Neuteboom ST, Palladino MA. Cusack JC Jr, et al. Clin Cancer Res. 2006 Nov 15;12(22):6758-64. doi: 10.1158/1078-0432.CCR-06-1151. Clin Cancer Res. 2006. PMID: 17121896 - The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A, Iaffaioli RV, Caponigro F. Milano A, et al. Eur J Cancer. 2007 May;43(7):1125-33. doi: 10.1016/j.ejca.2007.01.038. Epub 2007 Mar 26. Eur J Cancer. 2007. PMID: 17379504 Review. - The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. Milani M, et al. Cancer Res. 2009 May 15;69(10):4415-23. doi: 10.1158/0008-5472.CAN-08-2839. Epub 2009 May 5. Cancer Res. 2009. PMID: 19417138
Cited by
- Heat Shock Proteins and Ferroptosis.
Liu Y, Zhou L, Xu Y, Li K, Zhao Y, Qiao H, Xu Q, Zhao J. Liu Y, et al. Front Cell Dev Biol. 2022 Apr 11;10:864635. doi: 10.3389/fcell.2022.864635. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35478955 Free PMC article. Review. - Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.
Loaiza-Bonilla A, Furth EE, Morrissette JJ. Loaiza-Bonilla A, et al. Hepat Oncol. 2015 Oct;2(4):359-370. doi: 10.2217/hep.15.20. Epub 2015 Nov 11. Hepat Oncol. 2015. PMID: 30191018 Free PMC article. Review. - Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Drews O, Taegtmeyer H. Drews O, et al. Antioxid Redox Signal. 2014 Dec 10;21(17):2322-43. doi: 10.1089/ars.2013.5823. Epub 2014 Oct 1. Antioxid Redox Signal. 2014. PMID: 25133688 Free PMC article. Review. - Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Nooka A, Gleason C, Casbourne D, Lonial S. Nooka A, et al. Biologics. 2013;7:13-32. doi: 10.2147/BTT.S24580. Epub 2013 Jan 30. Biologics. 2013. PMID: 23386784 Free PMC article. - Ubiquitination-dependent regulation of signaling receptors in cancer.
Huangfu WC, Fuchs SY. Huangfu WC, et al. Genes Cancer. 2010 Jul;1(7):725-34. doi: 10.1177/1947601910382901. Genes Cancer. 2010. PMID: 21127735 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical